Wachtell, Lipton, Rosen & Katz served as legal adviser for
Ropes & Gray advised ImmunoGen in the deal that Bloomberg News said is aimed at gaining access to come of the hottest new drugs in the growing cancer market.
Healthcare and pharmaceutical deals have been a bright spot in a slow deals market. That can be attributed in part to cash holdings strategic acquirers have from their sales of Covid vaccines and therapies.
In March, Pfizer Inc. announced its acquisition of Seagen Inc. for approximately $43 billion. In February, CVS Health Corp. announced its acquisition of Oak Street Health Inc. for $10.6 billion.
Ropes mergers and acquisitions partner Tara Fisher and executive compensation partner Renata Ferrari led the firm’s team on the Abbvie deal, along with litigation and enforcement partners Mike McFalls and Ruchit Patel, IP transactions partner David McIntosh and finance partner Dan Coyne.
Fried Frank advised Goldman Sachs & Co. and Lazard as financial advisors to ImmunoGen. Its team was led by partners Philip Richter and Roy Tannenbaum.
To contact the reporter on this story:
To contact the editors responsible for this story:
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.